NASDAQ:NK - Nantkwest Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.35 -0.10 (-6.90 %) (As of 12/14/2018 04:00 PM ET)Previous Close$1.45Today's Range$1.34 - $1.4752-Week Range$1.34 - $5.47Volume232,500 shsAverage Volume288,358 shsMarket Capitalization$114.88 millionP/E Ratio-1.13Dividend YieldN/ABeta3.09 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. Receive NK News and Ratings via Email Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NK Previous Symbol CUSIPN/A Webwww.nantkwest.com Phone858-633-0300 Debt Debt-to-Equity Ratio0.04 Current Ratio3.31 Quick Ratio3.31 Price-To-Earnings Trailing P/E Ratio-1.13 Forward P/E Ratio-1.03 P/E GrowthN/A Sales & Book Value Annual Sales$50,000.00 Price / Sales2,139.21 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book0.49 Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-96,420,000.00 Net Margins-198,790.38% Return on Equity-54.20% Return on Assets-46.28% Miscellaneous Employees139 Outstanding Shares79,230,000Market Cap$114.88 million OptionableOptionable Nantkwest (NASDAQ:NK) Frequently Asked Questions What is Nantkwest's stock symbol? Nantkwest trades on the NASDAQ under the ticker symbol "NK." How were Nantkwest's earnings last quarter? Nantkwest Inc (NASDAQ:NK) issued its earnings results on Monday, August, 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $0.10 million. Nantkwest had a negative return on equity of 54.20% and a negative net margin of 198,790.38%. View Nantkwest's Earnings History. When is Nantkwest's next earnings date? Nantkwest is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Nantkwest. What price target have analysts set for NK? 2 brokerages have issued twelve-month target prices for Nantkwest's stock. Their forecasts range from $2.00 to $3.50. On average, they anticipate Nantkwest's share price to reach $2.75 in the next year. This suggests a possible upside of 103.7% from the stock's current price. View Analyst Price Targets for Nantkwest. What is the consensus analysts' recommendation for Nantkwest? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nantkwest. Has Nantkwest been receiving favorable news coverage? News stories about NK stock have been trending somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nantkwest earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of Nantkwest's key competitors? Some companies that are related to Nantkwest include PDL BioPharma (PDLI), CASI Pharmaceuticals (CASI), Translate Bio (TBIO), Mesoblast (MESO), La Jolla Pharmaceutical (LJPC), Cellular Biomedicine Group (CBMG), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Krystal Biotech (KRYS), Nightstar Therapeutics (NITE), Agenus (AGEN), LogicBio Therapeutics (LOGC), Gamida Cell (GMDA), Adverum Biotechnologies (ADVM) and Surface Oncology (SURF). Who are Nantkwest's key executives? Nantkwest's management team includes the folowing people: Dr. Patrick Soon-Shiong FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 65)Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 53)Mr. Richard J. Tajak, Consultant (Age 65)Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 45)Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 61) When did Nantkwest IPO? (NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager. Who are Nantkwest's major shareholders? Nantkwest's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.88%), Dimensional Fund Advisors LP (0.31%), Bridgeway Capital Management Inc. (0.22%), Bank of New York Mellon Corp (0.19%) and JPMorgan Chase & Co. (0.14%). View Institutional Ownership Trends for Nantkwest. Which institutional investors are selling Nantkwest stock? NK stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. View Insider Buying and Selling for Nantkwest. Which institutional investors are buying Nantkwest stock? NK stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bridgeway Capital Management Inc., JPMorgan Chase & Co. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Nantkwest. How do I buy shares of Nantkwest? Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nantkwest's stock price today? One share of NK stock can currently be purchased for approximately $1.35. How big of a company is Nantkwest? Nantkwest has a market capitalization of $114.88 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Nantkwest employs 139 workers across the globe. What is Nantkwest's official website? The official website for Nantkwest is http://www.nantkwest.com. How can I contact Nantkwest? Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected] MarketBeat Community Rating for Nantkwest (NASDAQ NK)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 198 (Vote Outperform)Underperform Votes: 186 (Vote Underperform)Total Votes: 384MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: What are retained earnings?